FDA Might Seek "Intermediate" Action Authority To Enforce Trial Compliance
This article was originally published in The Gray Sheet
FDA is considering whether to ask Congress for the authority to bring "intermediate" enforcement actions against parties violating clinical trial regs, FDA Office of Regulatory Affairs Director of Enforcement Daniel Michels told the Government Reform/Criminal Justice, Drug Policy and Human Resources Subcommittee.
You may also be interested in...
HHS plans to submit a legislative proposal to Congress by year-end that would authorize FDA to levy civil monetary penalties for infractions of human research subject protections rules, the Clinton administration announced May 23.
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.